1. Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109.
- Author
-
García-García V, Oldfield E, and Benaim G
- Subjects
- Adamantane pharmacology, Animals, Antitubercular Agents, Calcium metabolism, Cell Line, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical methods, Inhibitory Concentration 50, Leishmania mexicana metabolism, Macrophages drug effects, Macrophages parasitology, Mice, Adamantane analogs & derivatives, Antiprotozoal Agents pharmacology, Ethylenediamines pharmacology, Leishmania mexicana drug effects
- Abstract
We report that the tuberculosis drug SQ109 [N-adamantan-2-yl-N'-((E)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine] has potent activity against the intracellular amastigote form of Leishmania mexicana (50% inhibitory concentration [IC50], ∼11 nM), with a good selectivity index (>500). It is also active against promastigotes (IC50, ∼500 nM) and acts as a protonophore uncoupler, in addition to disrupting Ca(2+) homeostasis by releasing organelle Ca(2+) into the cytoplasm, and as such, it is an interesting new leishmaniasis drug hit candidate., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF